Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Tryp Therapeutics Inc (OP: TRYPF )

N/A UNCHANGED
Last Price Updated: 3:17 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tryp Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS at Massachusetts General Hospital
Via ACCESSWIRE
Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making
Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with... 
Via Benzinga
Tryp Submits IND Application To FDA For Clinical Trial Of Psilocybin-Assisted Psychotherapy In Patients With IBS
Tryp Therapeutics, Inc. (OTCQB: TRYPF) (CSE:TRYP) has submitted an Investigational New Drug application to the U.S. 
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Submits IND as Important Step in Advancing IBS Clinical Program
Via Investor Brand Network
Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital
Via ACCESSWIRE
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued 
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Closes on AUD $2.4M Oversubscribed Private Placement
Via Investor Brand Network
Tryp Therapeutics Secures $1.6M Via Oversubscribed Private Placement
Tryp Therapeutics Inc. (OTCQB: TRYPF) (CSE:TRYP), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high... 
Via Benzinga
Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Secured Convertible Debentures for Gross Proceeds of AUD$2,400,000
Via ACCESSWIRE
EXCLUSIVE: Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutionizing psychedelic therapy as a promising new approach for treating mental... 
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Private Placement for Minimum of AUD$2,000,000
Via Investor Brand Network
Therapists At Mass General Hospital Prepared To Assist IBS Patients With Psilocybin Therapy
Psychotherapists at the Massachusetts General Hospital (MGH) have undergone training by lead business Fluence toward participating in Tryp Therapeutics (OTCQB: T 
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Marks Significant Step in Advancing Potential Groundbreaking Treatment for IBS
Via Investor Brand Network
Tryp Therapeutics Completes Psychotherapy Training for Planned Phase 2a Clinical Trial at Massachusetts General Hospital
Via ACCESSWIRE
What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey. 
Via Benzinga
Psyched: NY Discusses Regulations, MDMA For PTSD Aims For Legalization, Shrooms For Eating Disorders & More
Guess Which East Coast State Is Now Discussing Legalizing Psychedelics? Decriminalizing psychedelics is one thing, but fully legalizing them is another. That's currently a measure before New York's... 
Via Benzinga
Treating Binge Eating Disorder With Magic Mushrooms: Phase 2 Clinical Trial Gets Thumbs Up
Clinical-stage psychedelics biotech Tryp Therapeutics, Inc. 
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Interim Results, Encouraging Trends for Phase II STOP Trial
Via Investor Brand Network
Tryp Therapeutics Announces Interim Results for Its Phase II Clinical Trial for the Treatment of Binge Eating Disorder With Psilocybin-Assisted Psychotherapy
Via ACCESSWIRE
Business & Academia Join Forces To Study Magic Mushroom Therapy For IBS Patients
Psychedelics company Tryp Therapeutics Inc. 
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), MGH to Collaborate in Clinical Study Investigating Psilocybin-Assisted Psychotherapy for IBS Patients
Via Investor Brand Network
Tryp Therapeutics and Massachusetts General Hospital Sign Letter of Intent for Clinical Study Investigating the Use of Psilocybin-Assisted Psychotherapy for the Treatment of Patients Suffering From Irritable Bowel Syndrome (IBS)
Via ACCESSWIRE
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at Biotech Showcase
Via Investor Brand Network
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases FY 2022 Financial, Corporate Report
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Participate in Upcoming Online Investor Conference
Via Investor Brand Network
Tryp Therapeutics to Webcast Live at VirtualInvestorConferences.com on Thursday, December 15
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Poster Presentations for Upcoming SfN Conference
Via Investor Brand Network
This Psychedelics Company Is Patenting Its Psilocin And Psilocybin Delivery Route
The World Intellectual Property Organization (WIPO) has published clinical-stage biopharma Tryp Therapeutics Inc. (OTCQB: TRYPF)’s international patent application for the intravenous (IV)... 
Via Benzinga
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Notes WIPO Publication of International PCT Patent Application
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.